Discussion  by unknown
Melby et al Acquired Cardiovascular Diseaseelucidatewhich causative factors of PH have the highest im-
pact on outcome.SUMMARY
In patients undergoing AVR for aortic stenosis, PH
increased operative and long-term mortality. Earlier
intervention—before irreversible changes in the pulmonary
circulation can occur—should be considered for asymptom-
atic or minimally symptomatic patients with significant aor-
tic stenosis and moderate to severe PH. It is important for
surgeons to consider PH in preoperative risk assessment
of patients undergoing AVR.A
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Dr James S. Gammie (Baltimore, Md). Dr Melby and col-
leagues from Washington University are to be congratulated on
a well-presented study. Previous work has clearly demonstrated
that unoperated aortic stenosis with PH is associated with a partic-
ularly dismal prognosis. It is also clear from the literature that
development of PH in patients with aortic stenosis is associated
with the presence of symptoms, a decline in left ventricular sys-
tolic ejection performance, and, most importantly and closely,
with diastolic dysfunction as measured by elevated LVEDP and
echocardiographic indices of impaired left ventricular relaxation.
PH has not been included in risk models assessing the outcomes
after AVR, and thus this work contributes to the literature. The cur-
rent Society of Thoracic Surgeons risk models do not include PAP
because this variable is infrequently collected, and, in fact, in re-
cent years has only been collected in 30% of patients. There is
clear room for improvement here.
I would like to emphasize a key finding of your study, which
was more clear in the manuscript than in the presentation: your
multivariable models demonstrated that the presence of PH was
not a risk factor for perioperative mortality, and thus we can
conclude that PH in patients with aortic stenosis compromises
long-term survival but not short-term surgical outcomes.
Your study was heterogeneous in that it included both isolated
AVRs as well as AVRs performed with CABG. Did you look at
your isolated aortic valve population and did you find that PH
had a similar impact on outcomes?
Dr Melby. Thank you, Dr Gammie. With respect to the perio-
perative mortality, our perioperative mortality did almost double,
but the review with multivariate analysis did not show that it
was an independent risk factor. We did not have the chance to
go back—and it is certainly something we will look at in the fu-
ture—to look at just the patients who had only AVR. As you
saw, that was about half of our patients. We have encountered
the problem that you mentioned, which is that it is not a frequently
reported number. As you start to cut your group down, you start to
lose patients and you have weaker results. We looked at the entire
group and not exclusively at those who had only AVR, but
certainly that would be worth looking at in the future.diovascular Surgery c Volume 141, Number 6 1429
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C
DDr Gammie. Did you look separately at your subset of patients
that had more significant PH, those that you classified as moderate
or severe?
DrMelby.Whenwe did our Kaplan–Meier analysis, we created
categories of mild, moderate, and severe PH and found that those
with more significant PH indeed had a significantly worse long-
term survival. When we looked at the perioperative mortality,
once again, it was not a significant independent risk factor,
although it was a significant univariate risk factor. Likely, the in-
creased risk of perioperative death is associated with the multiple
comorbidities.
Dr Gammie. This series spanned 13 years, during which time
greater use of nitric oxide and intravenous phosphodiesterase in-
hibitors occurred. In addition to these modalities, there are now
3 classes of oral medications available to treat PH, including pros-
tacyclins, endothelin receptor antagonists, and oral phosphodies-
terase inhibitors. Given your findings and the impressive fact
that half of these patients are dead 5 years after surgery, do you
think that we should consider treating these patients after heart
valve surgery much as we treat post-CABG patients, with statins?
Also, do you think these results would have an impact on indica-
tions for AVR?
Dr Melby. Thank you. Indeed, we have been treating PH more
aggressively and using some of the medications that you men-
tioned, nitric oxide and epoprostenol, or Flolan, commonly in
the postoperative period. Unfortunately, there is very little litera-
ture on this and no one has looked specifically at the question
you asked. We have looked at our data and recognize that these
are important questions, specifically who needs to be treated. We
are trending toward looking preoperatively more on patients
with PH if they react to some of these medications because it
seems to be a trend that if you get a nitric challenge and your
PAP does not fall, you do more poorly with surgery. However,
these are difficult questions that are going to require more studies.
We have not done such studies yet, but we need to do so.
Dr Randall B. Griepp (New York, NY). You define PH in terms
of PAP rather than the resistance across the pulmonary vascular
bed, and consequently it has both the component of PVR per se
as well as left ventricular filling pressure. I wonder whether
a good part of this effect may just be that you are measuring a sur-
rogate for left ventricular failure, either the dilated systolically
failing ventricle or the very hypertrophied diastolically dysfunc-
tioning ventricle. That might also be an explanation as to why1430 The Journal of Thoracic and Cardiovascular Surthose patients whose PAP does not change postoperatively do so
poorly. I might suggest that perhaps those are the ones with the se-
verely hypertrophied ventricles in whom the major issue is really
diastolic dysfunction, which does not clear very quickly.
Dr Melby. Thank you. I appreciate those comments. From my
slides, I can show you a graph indicating that we indeed looked at
patients with increased PVR, trying to answer the exact question
you are asking. Those with an elevated PVR we have separated
into greater than 3 Wood units or less than 3 Wood units, trying
to tease out what is the left ventricular involvement in this. Those
with the higher PVR also did worse, similar to the response of the
group with just high PH.
Dr Kevin D. Accola (Orlando, Fla). Dr Melby, to elaborate on
Drs Gammie and Griepp’s comments, can you apply this clinically
now? How have you looked at your patients, particularly those
with severe PH? Have you designed a strategy clinically to preop-
eratively evaluate these or use provocative testing to see which
patients truly have reactive PH relative to their left ventricular
dysfunction or truly fixed PH, which I think is another subset
and particularly a higher risk category?
DrMelby. That is an excellent question. We have indeed begun
to implement some of these findings in our preoperative workup
and we have had provocative testing. However, there is very little
published on this, and it is mostly just done by the feelings of the
individual surgeon and by our preoperative planning team. We
happen to have a nice preoperative planning group devised of an-
esthesiologists who are very interested in PH. We have looked at
this in some patients, and it only takes a few cases of severe PH
to go bad for you to realize there is something different with these
patients. Thus we are trying to tease those patients out and find out
which ones might be higher risk. I do not have any great answers
yet, but it is certainly something that needs to be looked at.
Dr Irene Cybulsky (Hamilton, Ontario, Canada). Have you
looked at the etiology of the PH, whether it was cardiac or respi-
ratory? Also have you looked at associated tricuspid regurgitation
with the degree of PH?
Dr Melby. That is a very good question, and you bring up
a good point in that the etiology of PH can be multifactorial.
Unfortunately with the database that we have, there is just no
way to find all the answers to the questions you ask. Once again,
there is a paucity of literature on this, and this is a great opportunity
to find out which factors are going to tease out to be the most
significant ones.gery c June 2011
